Parkinson’s Disease and Gene Therapy


  • Mustafa Mahmud Amin Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Aldy S. Rambe Department of Neurology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Kiking Ritarwan Department of Neurology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia



Parkinson’s disease, Dopamine, Genetic therapy


Since its introduction for more than a century, Parkinson’s disease has caught attention in the field of neuroscience. From the beginning of understanding its pathogenesis of dopamine pathways, many studies have grown in finding the treatment of the disease. In the beginning, medications showed promise results until each of them had its limitation in treating the disease. Another focus of attention from studies in the last decade was from gene therapy, and early phases of studies have shown some pledging moments for the disease.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Ropper AH, Samuels MA. Adams and Victors Principles of Neurology. 9th ed. New York: McGraw-Hill; 2009.

Apetauerova D. Parkinson’s disease. In: Jones HR Jr., Srinivasan J, Allam GJ, Baker RA, editors. Netter’s Neurology. 2nd ed., Ch. 33. Philadelphia, PA: Elsevier, Saunders; 2012.

Wilkinson I, Lennox G. Essential Neurology. 4th ed. Massachusetts: Blackwell Publishing, Inc.; 2005.

Chauduri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol. 2006;5(3):235-45. PMid:16488379 DOI:

Stahl SM. Stahl’s Essential Psychopharmacology Neuroscientific Basis and Clinical Applications. 3rd ed. New York: Cambridge University Press; 2008.

Fernandez-Espejo E. Pathogenesis of Parkinson’s disease. Mol Neurobiol. 2004;29(1):15-30. DOI:

Witt J, Marks WJ Jr. An Update on gene therapy in Parkinson’s disease. Curr Neurol Neurosci Rep. 2011;11(4):362-70. PMid:21479996 DOI:

The National Collaborating Centre for Chronic Conditions. Parkinson’s Disease. National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians; 2006.

Dauer W, Przedborski S. Parkinson’s disease: Mechanisms and models. Neuron. 2003;39(6):889-909. PMid:12971891 DOI:

Mink JW. The basal ganglia. In: Squire L, Berg D, Bloom F, du Lac S, Ghosh A, Spitzer NC, editors. Fundamental Neuroscience. 3rd ed., Ch. 31. Canada: Academic Press; 2008.

Fuller G, Manford M. Neurology an Illustrated Colour Text. 3rd ed. Edinburgh: Churchill Livingstone; 2010.

Purves D, Augustine GJ, Fitzpatrick D, Hall WC, LaMantia AS, McNamara JO, et al., editors. Modulation of movement by the basal ganglia. In: Neuroscience. 5th ed., Ch. 18. Sunderland: Sinauer Associates, Inc.; 2012.<871::aid-bies15>;2-f DOI:<871::AID-BIES15>3.0.CO;2-F

Eberhardt O, Schulz JB. Gene therapy in Parkinson’s disease. Cell Tissue Res. 2004;318:243-60. DOI:

Horrelou P, Mallet J. Gene therapy for Parkinson’s disease. Mol Neurobiol. 1997;15(2):241-56. DOI:

Ralph GS, Binley K, Wong LF, Azzouz M, Mazarakis ND. Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors. Clin Sci. 2006;110:37-46. PMid:16336203 DOI:

Berry AL, Foltynie T. Gene therapy: A viable therapeutic strategy for Parkinson’s disease? J Neurol. 2011;258(2):179-88. PMid:20963433 DOI:




How to Cite

Amin MM, Rambe AS, Ritarwan K. Parkinson’s Disease and Gene Therapy. Open Access Maced J Med Sci [Internet]. 2021 Jun. 7 [cited 2024 Apr. 21];9(T3):60-3. Available from:

Most read articles by the same author(s)

1 2 3 > >>